<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38648456</article-id><article-id pub-id-type="pmc">PMC467028</article-id>
<article-id pub-id-type="publisher-id">IJO-72-482</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_3333_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Repeat corneal transplantation in Southern China: Indications, surgical technique, outcomes, and risk factors for repeat keratoplasty failure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Qiaolan</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Qinxiang</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wuhe</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jinyang</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Zelin</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Haiou</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Dan</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1">National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Prof. Wei Chen, Eye Hospital of Wenzhou Medical University, 270# West Xueyuan Road, Wenzhou, Zhejiang Province, China. E-mail: <email xlink:href="chenweimd@wmu.edu.cn">chenweimd@wmu.edu.cn</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>4</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S482</fpage><lpage>S487</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>12</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2024</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>To report the indications, surgical techniques, and outcomes of repeat keratoplasty and evaluate the risk factors for graft failure in the Chinese population.</p></sec><sec id="st2"><title>Methods:</title><p>The medical records of 216 patients (243 cases) who underwent at least two keratoplasties at a leading eye hospital in southern China between 2011 and 2020 were retrospectively reviewed. Indications and surgical procedures for repeat corneal transplantation were analyzed. Kaplan&#x02013;Meier survival analysis was used to determine the graft survival rate after repeat keratoplasty. A multivariable survival model was used to assess the risk factors.</p></sec><sec id="st3"><title>Results:</title><p>Repeated keratoplasties increased continuously from 2011 to 2020 (<italic toggle="yes">P</italic> = 0.002). The most common primary indication was infectious keratitis (38.7%), and the most common reason for repeat keratoplasty was graft rejection (30.04%). Regraft techniques included penetrating keratoplasty (PK) in 165 cases (67.9%), deep lamellar keratoplasty (DALK) in 52 cases (21.40%), and endothelial keratoplasty (EK) in 26 cases (10.7%). Median survival was 5.3, 6.8, and 6.4 years for PK, DALK, and EK, respectively. The 5-year survival rate was 53.5%, 66.6%, and 69.8% for PK, DALK, and EK, respectively. The median LogMAR visual acuity was 1.4 for PK, 0.75 for DALK, and 1.2 for EK at the end of the follow-up. Multivariate analysis revealed that graft rejection is a risk factor for repeat keratoplasty failure (<italic toggle="yes">P</italic> = 0.002).</p></sec><sec id="st4"><title>Conclusions:</title><p>DALK and EK may provide better outcomes than PK in treating graft failure. Preventing and treating postoperative graft rejection may be key to improving regraft survival. These findings will aid in the management of failed corneal grafts.</p></sec></abstract><kwd-group><kwd>Graft survival</kwd><kwd>repeat keratoplasty</kwd><kwd>risk factors for graft failure</kwd><kwd>visual outcome</kwd></kwd-group></article-meta></front><body><p>Corneal blindness can cause reversible blindness and can be managed by healthy donor cornea transplantation. With the use of keratoplasty and increasing life expectancy, regrafting is now a common indication for keratoplasty in developed countries[<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref>] and has been on the rise in developing countries[<xref rid="R4" ref-type="bibr">4</xref><xref rid="R5" ref-type="bibr">5</xref>] in recent decades. Repeat keratoplasty is technically more challenging and has lower graft survival rates than initial keratoplasty procedures, with graft survival rates ranging from 28% to 81% after repeat corneal transplantation.[<xref rid="R6" ref-type="bibr">6</xref><xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref><xref rid="R9" ref-type="bibr">9</xref>] Few studies on repeat corneal transplantation outcomes and risk factors have been conducted.[<xref rid="R9" ref-type="bibr">9</xref><xref rid="R10" ref-type="bibr">10</xref>] Studies on repeat keratoplasty in China are limited, especially regarding the outcomes and risk factors for graft failure in repeat corneal transplants.</p><p>We aimed to quantify the number of repeat keratoplasties performed at one of the largest corneal transplant centers in China to analyze the indications and surgical techniques and to investigate the outcomes and factors influencing the risk of repeat graft failure.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><sec id="sec2-1"><title>Study subjects</title><p>Cases of repeat keratoplasty performed at a leading eye hospital in southern China from January 1, 2011, to December 31, 2020, were included. Eyes with two or more repeat keratoplasties were categorized as having multiple repeat keratoplasties. The demographic data, primary indications, direct reasons, and surgical procedures for repeat keratoplasty were reviewed retrospectively. The length of time between the primary graft and the regraft and the size of the regraft were recorded. Ophthalmologic procedures, including glaucoma and cataract surgery, ocular comorbidities, including glaucoma and corneal neovascularization, and systemic conditions, including hypertension and diabetes, were also noted. Postoperative graft clarity was also recorded at every visit.</p><p>The primary outcomes were graft survival and best-corrected visual acuity (BCVA) after repeat keratoplasty and the risk factors associated with regraft failure. Rates of repeat keratoplasty and graft complications were also evaluated. This study adhered to the tenets of the Declaration of Helsinki and was approved by our institutional ethics committee.</p></sec><sec id="sec2-2"><title>Classification and definition</title><p>The primary indications for keratoplasty in this study were categorized as follows: infectious keratitis, non-infectious keratitis, bullous keratopathy, corneal malnutrition, keratoconus, corneal leukoma, corneal trauma, corneal tumors, and other causes. Bacterial, viral, fungal, amoebic, and unknown pathogens cause infectious keratitis. Corneal dystrophies include Fuchs&#x02019; endothelial dystrophy and other dystrophies involving the corneal stroma. Corneal leukoplakia characterizes congenital corneal opacities and scarring. Corneal trauma can include thermal, mechanical, or chemical injury.</p><p>The direct reasons for repeat keratoplasty were as follows: primary condition recurrence, graft dissolution, opacification, rejection, endothelial decompensation, graft infection (excluding primary condition recurrence), trauma, and unspecified indications. Graft rejection was diagnosed as graft edema occurring more than 2 weeks postoperatively and the presence of at least one of the following signs: endothelial rejection lines, infiltrating corneal debris, or anterior segment inflammation. Endothelial decompensation was defined as an irreversible decrease in endothelial cell density and loss of graft clarity.</p><p>Three keratoplasty procedures were performed: penetrating keratoplasty (PK), deep lamellar keratoplasty (DALK), and endothelial keratoplasty (EK).</p><p>Graft failure was defined as the irreversible central opacity of a previously clear corneal graft postoperatively. Graft survival was defined as the time to graft failure or end of follow-up.</p></sec><sec id="sec2-3"><title>Statistical analysis</title><p>Statistical analyses were performed using SPSS version 24.0 (IBM Corp., Armonk, NY, USA). Categorical data are presented as frequencies (n) and percentages (%). Visual acuity was converted into LogMAR for statistical analysis. Baseline characteristics were compared for the three surgical techniques by using Fisher&#x02019;s exact test for count data, and the Mann-Whitney test was performed for continuous data. The Pearson correlation coefficient was used to analyze trends in the annual number of repeat keratoplasties. Graft survival rates were analyzed using Kaplan&#x02013;Meier survival curves, and the differences between groups were compared using the log-rank test. A Wilcoxon signed rank test was performed to compare pre- and postoperative VA and for different types of regrafts. We applied the Cox proportional hazards model to determine the hazard ratio (HR) and corresponding 95% confidence interval (95% CI) to identify potential risk factors associated with the subsequent failure of repeat keratoplasty. A two-sided <italic toggle="yes">P</italic> value of &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><sec id="sec2-4"><title>Demographics</title><p>In total, 243 cases of repeat corneal transplantation involving 216 patients were included, of whom 142 were male (65.74%) and 74 were female (34.26%). The median age at the time of surgery was 56 (interquartile range [IQR]: 43&#x02013;66) years. The median interval between the first and repeat keratoplasty was 2 (IQR: 0.5&#x02013;5) years. The median size of regrafts was 8 (IQR: 7.75&#x02013;8 mm) mm. The above-baseline characteristics were comparable between the three surgical techniques [<xref rid="IJO.IJO_3333_23-ST1" ref-type="table">Supplemental Table 1</xref>]. The median follow-up duration was 17 (IQR: 7&#x02013;3) months. Among the 243 repeat corneal transplant cases, 202 (83.13%) underwent the procedure once, 33 (13.58%) twice, seven (2.88%) three times, and one (0.41%) four times.</p><table-wrap position="float" id="IJO.IJO_3333_23-ST1"><label>Supplemental Table 1</label><caption><p>Baseline characteristics comparing repeat PK, DALK, and EK</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">PK</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">DALK</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">EK</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age (y)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (male:female)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">112:165</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">32:20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14:12</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.330</td></tr><tr><td align="left" rowspan="1" colspan="1">Median (IQR) duration between first and repeat graft (y)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (1.2&#x02013;5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.5 (0.7&#x02013;5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.2 (1&#x02013;4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.120</td></tr><tr><td align="left" rowspan="1" colspan="1">Size of regraft (mm)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8 (7.7&#x02013;8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7.7 (7.7&#x02013;8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8 (7.7&#x02013;8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.687</td></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>PK: Penetrating keratoplasty, DALK: Deep lamellar keratoplasty, endothelial keratoplasties EK: Endothelial keratoplasty, IQR: Interquartile range</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-5"><title>Primary indications and direct reasons for repeat corneal transplantation</title><p>As presented in <xref rid="IJO.IJO_3333_23-T1" ref-type="table">Table 1</xref>, the most common primary indications were infectious keratitis (n = 94, 36.68%), including viral keratitis (n = 67, 27.57%), fungal keratitis (n = 13, 5.35%), bacterial keratitis (n = 11, 4.53%), and acanthamoeba keratitis (n = 3, 1.23%). Corneal leukoma was the second most common primary indication (n = 48, 19.75%).</p><table-wrap position="float" id="IJO.IJO_3333_23-T1"><label>Table 1</label><caption><p>Primary indications and direct reasons for repeat keratoplasty</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Primary indications</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Direct reasons</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Infectious keratitis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">94 (36.68)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft rejection</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">73 (30.04)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal leukoma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">48 (19.75)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Endothelial decompensation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">54 (22.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bullous keratopathy</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33 (13.58)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Recurrence</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">41 (16.87)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal malnutrition</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24 (9.88)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft infection</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">38 (15.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal trauma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17 (7)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft opacification</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20 (8.23)</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-infectious keratitis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11 (4.53)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft dissolution</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14 (5.76)</td></tr><tr><td align="left" rowspan="1" colspan="1">Keratoconus</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10 (4.12)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (1.23)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal tumors</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (1.23)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (1.23)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>The direct reasons for repeat corneal transplantation are listed in <xref rid="IJO.IJO_3333_23-T1" ref-type="table">Table 1</xref>, with graft rejection being the most common reason for regrafting (n = 73, 30.04%), followed by primary corneal endothelial decompensation (n = 54, 22.22%).</p><p>Primary indications and direct reasons for multiple regrafts are listed in <xref rid="IJO.IJO_3333_23-ST2" ref-type="table">Supplemental Table 2</xref>. The most common primary indications were infectious keratitis and bullous keratopathy, while the most common reason for regrafting was graft rejection.</p><table-wrap position="float" id="IJO.IJO_3333_23-ST2"><label>Supplemental Table 2</label><caption><p>Primary indications and direct reasons for multiple regrafts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Primary indications</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Direct reasons</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Infectious keratitis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11 (26.83)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft rejection</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16 (39.02)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bullous keratopathy</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11 (26.83)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Endothelial decompensation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9 (21.95)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal leukoma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7 (17.07)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Recurrence</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8 (19.51)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal malnutrition</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 (12.20)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft infection</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (7.32)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal trauma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 (12.20)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft opacification</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (4.88)</td></tr><tr><td align="left" rowspan="1" colspan="1">Keratoconus</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (2.44)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (4.88)</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal tumors</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (2.44)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Graft dissolution</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (2.44)</td></tr></tbody></table></table-wrap></sec><sec id="sec2-6"><title>Procedures of corneal transplantation</title><p>Between January 2011 and December 2020, 2577 corneal transplants were performed, with 243 (9.42%) being repeat corneal transplants. The annual count of repeat corneal transplantations significantly increased during the study period (r = 0.853, <italic toggle="yes">P</italic> = 0.002; <xref rid="IJO.IJO_3333_23-F1" ref-type="fig">Fig. 1</xref>). PK remained the primary surgical approach for repeat corneal transplants, while the proportion of EK showed an increasing trend (r = 0.520, <italic toggle="yes">P</italic> = 0.123; <xref rid="IJO.IJO_3333_23-F1" ref-type="fig">Fig. 1</xref>), and DALK showed a decreasing trend (r = &#x02212;0.415, <italic toggle="yes">P</italic> = 0.233).</p><fig position="float" id="IJO.IJO_3333_23-F1"><label>Figure 1</label><caption><p>(a) Annual number of repeat PK, DALK, and EK from 2011 to 2020. (b) The proportion of EK in repeat keratoplasty demonstrated an increasing trend</p></caption><graphic xlink:href="IJO-72-482-g001" position="float"/></fig><p>PK was performed in 165 cases (67.90%), DALK in 52 (21.40%), and EK in 26 (10.70%). In cases of PK failure, the predominant choice for subsequent repeat corneal transplantation was PK, followed by EK. For DALK failure, the preferred procedure for subsequent repeat corneal transplantation was DALK, followed by PK. For EK failure, PK was the primary choice for subsequent repeat corneal transplantation, followed by EK [<xref rid="IJO.IJO_3333_23-ST3" ref-type="table">Supplemental Table 3</xref>].</p><table-wrap position="float" id="IJO.IJO_3333_23-ST3"><label>Supplemental Table 3</label><caption><p>Surgical procedures for primary and repeat keratoplasty</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Primary keratoplasty</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="5" rowspan="1">Repeat keratoplasty<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">Total</th></tr><tr><th align="center" rowspan="1" colspan="1">PK</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">DALK</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">EK</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PK</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">129 (85.43%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 (2.65%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18 (11.92%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">151 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALK</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">28 (28.57%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">48 (62.33%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (1.30%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">77 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">EK</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8 (53.33%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7 (46.67%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15 (100%)</td></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>PK: Penetrating keratoplasty, DALK: Deep lamellar keratoplasty, endothelial keratoplasties EK: Endothelial keratoplasty</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-7"><title>Complications of repeat corneal transplantation</title><p>During the follow-up period, graft rejection was the most common complication in 62 cases (25.51%). The interval between transplantation and rejection ranged from 0.66 to 92 months, with a mean interval of 16.85 &#x000b1; 18.48 months. Among the rejected cases, graft clarity after anti-rejection treatment was achieved in 28 (45.16%) patients. However, graft failure occurred in 34 cases despite aggressive anti-rejection treatment. We analyzed the relationship between glaucoma, corneal neovascularization, concurrent surgery, systemic disease, and rejection. Cases with corneal neovascularization exhibited higher rates of rejection than those without corneal neovascularization (<italic toggle="yes">P</italic> = 0.028).</p><p>Graft failure occurred in 49 cases after repeat PK. The causes of failure included 26 (53.06%) cases of rejection, 12 (24.49%) cases of graft opacification, eight (16.33%) cases of infectious keratitis, two (4.08%) cases of graft dissolution, and one (2.04%) case of endothelial decompensation. Graft failure occurred in 16 cases after repeat DALK. The causes of failure included five (31.35%) cases of graft opacification, five (31.35%) cases of rejection, three (18.75%) cases of infectious keratitis, two (12.50%) cases of graft dissolution, and one (6.25%) case of endothelial decompensation. Graft failure occurred in six cases after repeat EK. The causes of failure included three (50%) cases of rejection, two (33.33%) cases of graft opacification, and one (16.67%) cases of endothelial decompensation.</p><p>The second most common complication was elevated postoperative intraocular pressure (IOP), which occurred in 37 cases (15.22%). IOP could be controlled with medication in most cases, except in three patients who underwent vitrectomy for intraocular inflammation.</p></sec><sec id="sec2-8"><title>Outcomes and risk factor</title><p>Overall median survival was 6 years, with a survival rate of 84.5% at 1 year and 59.1% at 5 years. The first regrafts survived for a median of 6 years, and multiple regrafts survived for 3.3 years. The Kaplan&#x02013;Meier curve showed that the cumulative survival proportion was similar for the first and multiple regrafts during the first year after transplantation. Thereafter, it declined faster for multiple regrafts, from 62.7% for the first regrafts to 35.3% for multiple regrafts at the end of 5 years [<xref rid="IJO.IJO_3333_23-F2" ref-type="fig">Fig. 2</xref>]. However, the difference was insignificant according to the log-rank test (<italic toggle="yes">P</italic> = 0.191).</p><fig position="float" id="IJO.IJO_3333_23-F2"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier cumulative proportion of graft survival in the first and multiple regrafts</p></caption><graphic xlink:href="IJO-72-482-g002" position="float"/></fig><p>The outcomes of three surgical techniques are listed in <xref rid="IJO.IJO_3333_23-ST4" ref-type="table">Supplemental Table 4</xref>. Median survival was 5.3 years for PK, 6.8 years for DALK, and 6.4 years for EK. The Kaplan&#x02013;Meier curve showed that the cumulative survival proportion was 87.9% for PK during the first year after transplantation, slightly higher than that for DALK (75.2%) and EK (82.7%). Subsequently, graft survival declined faster for PK and was 53.5% for PK, 66.6% for DALK, and 69.8% for EK at the end of 5 years. At 7 years, graft survival remained stable for DALK and EK but dropped to 28.5% for PK [<xref rid="IJO.IJO_3333_23-F3" ref-type="fig">Fig. 3</xref>]. However, the log-rank test did not show a significant difference (<italic toggle="yes">P</italic> = 0.862), probably because of different trends over time.</p><fig position="float" id="IJO.IJO_3333_23-F3"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier cumulative proportion of graft survival of repeat PK, DALK, and EK</p></caption><graphic xlink:href="IJO-72-482-g003" position="float"/></fig><table-wrap position="float" id="IJO.IJO_3333_23-ST4"><label>Supplemental Table 4</label><caption><p>Outcomes of repeat PK, DALK, and EK</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Surgical techniques</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">1-year survival (%)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">5-year survival (%)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Survival time (y)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">LogMAR BCVA (IQR)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PK</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">87.9%</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">53.5%</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.4 (0.7&#x02013;2.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALK</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">75.2%</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">66.6%</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.75 (0.5&#x02013;1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">EK</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">82.7%</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">69.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.2 (0.7&#x02013;2.2)</td></tr></tbody></table><table-wrap-foot><fn id="TF-F3"><p>PK: Penetrating keratoplasty, DALK: Deep lamellar keratoplasty, endothelial keratoplasties EK: Endothelial keratoplasty, IQR: interquartile range</p></fn></table-wrap-foot></table-wrap><p>All cases had preoperative visual acuity records with a median BCVA of LogMAR 2.9. However, only 158 cases had postoperative BCVA records. For the cases that had both pre- and postoperative BCVA records, median BCVA improved from LogMAR 2.9 to 1.3 (<italic toggle="yes">P</italic> &#x0003c; 0.001) at the end of the follow-up. The median LogMAR BCVA was 1.4 for PK, 0.75 for DALK, and 1.2 for EK at the end of the follow-up. BCVA in DALK was significantly better than that in PK.</p><p>Cox regression analysis was used to analyze the risk factors associated with repeat keratoplasty failure [<xref rid="IJO.IJO_3333_23-T2" ref-type="table">Table 2</xref>]. In the multivariate regression analysis, graft rejection was a risk factor for repeat keratoplasty failure (HR = 2.623; 95% CI: 1.427&#x02013;4.826; <italic toggle="yes">P</italic> = 0.002).</p><table-wrap position="float" id="IJO.IJO_3333_23-T2"><label>Table 2</label><caption><p>Risk factors for regraft failure</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Univariate<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Multivariate<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">HR</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1">HR (95%CI)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.093</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.738</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.004</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.557</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary indication</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.827</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.480</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Regraft number</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.559</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.161</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Duration between primary and repeat graft</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.942</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.824</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Graft size</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.580</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.938</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Systemic disease</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.980</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.953</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Previous glaucoma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.296</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.091</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Corneal neovascularization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.970</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.910</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Concurrent surgical procedure</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.636</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.332</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative high IOP</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.934</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.833</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Graft rejection</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.160</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.624 (1.427&#x02013;4.826)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn id="TF-F4"><p>HR: Hazard ratio, IOP: Intraocular pressure</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>Repeat keratoplasty has become increasingly common in developed and developing countries, including China, over the last decade. This study is the first to evaluate graft survival and risk factors for graft failure after long-term repeat keratoplasty in a Chinese population.</p><p>We reviewed the annual data of keratoplasties performed at a leading eye hospital in southern China over the past 10 years, with 2577 grafts, including 243 regrafts. The overall percentage of repeat corneal transplants was 9.4%, which was slightly higher than the proportion of regrafts performed in other large centers in China.[<xref rid="R4" ref-type="bibr">4</xref><xref rid="R11" ref-type="bibr">11</xref>] When compared to New Zealand&#x02019;s 18.3%,[<xref rid="R10" ref-type="bibr">10</xref>] the United Kingdom&#x02019;s 21.1%[<xref rid="R12" ref-type="bibr">12</xref>] and Canada&#x02019;s 17.1%,[<xref rid="R13" ref-type="bibr">13</xref>] the proportion of repeat corneal transplants in China was relatively low. However, this study shows that the annual regrafting rate gradually increased from 2011 to 2020. As donor shortages ease and surgical techniques improve, repeat corneal transplants are expected to increase over the next decade.</p><p>In this study, infectious keratitis was the most common primary indication for keratoplasty, followed by corneal leukoma, accounting for 38.68% and 19.75% of cases, respectively. This trend is reasonable because the most common indications for keratoplasty in China have been infectious keratitis and corneal leukoma over the last three decades.[<xref rid="R11" ref-type="bibr">11</xref><xref rid="R14" ref-type="bibr">14</xref>] Keratoconus in New Zealand[<xref rid="R10" ref-type="bibr">10</xref>] and keratoconus and corneal dystrophy in France[<xref rid="R15" ref-type="bibr">15</xref>] have been reported to be the most common primary indications for repeat corneal transplantation, accounting for only 4.12% and 9.88% of the indications in this study, respectively, indicating that there are significant differences in the primary indications for repeat corneal transplantation between developing and developed countries. The most common reasons for repeat keratoplasty were graft rejection (30%) and endothelial decompensation (22.2%). This pattern has been similarly reported in both developing and developed countries.[<xref rid="R10" ref-type="bibr">10</xref><xref rid="R16" ref-type="bibr">16</xref>]</p><p>The majority of repeat keratoplasty procedures were PK (165, 67.9%), and the smaller were DALK (52, 21.4%) and EK (26, 10.7%), which is consistent with the sequence of primary corneal transplants. The number of EK surgeries performed increased between 2012 and 2020. Among regraft procedures following primary PKs, regraft PKs account for 85.43% of cases, follwed by regraft EKs at 11.92%. This trend agreed with the repeat corneal transplant surgical techniques reported by Dipika for New Zealand.[<xref rid="R10" ref-type="bibr">10</xref>] EK has been used as a method of repeat keratoplasty in developed countries since 2015.[<xref rid="R17" ref-type="bibr">17</xref>] The growing trend of EK surgery was also reported by an ophthalmology center in eastern China.[<xref rid="R16" ref-type="bibr">16</xref>] Our results show that EK has become an alternative to PK after failed PK surgery in China.</p><p>The mean survival period in this study was 5.1 years, with survival rates of 84.5% at 1 year and 59.1% at 5 years. To our knowledge, our study is the first on the survival rate after long-term repeat corneal transplantation in Chinese patients. Chen <italic toggle="yes">et al.</italic>[<xref rid="R18" ref-type="bibr">18</xref>] reported a 1-year survival rate of 85.2% and a 5-year survival rate of 79.2% for short-term repeat corneal transplants (repeat transplant intervals of 1 year or less) in eastern China. This implies that long-term graft survival may be higher for short-term repeat corneal transplants than long-term ones. This potential disparity could be because long-term graft failure tends to be related to chronic causes, including graft rejection or endothelial dystrophy, which, as in our study, may reduce repeated graft success rates.</p><p>Few studies have analyzed graft survival after repeat keratoplasty in PK and reported that the long-term survival of repeat PK varies from 50% to 66% at 5 years.[<xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref><xref rid="R10" ref-type="bibr">10</xref>] Very limited data have evaluated the outcomes of repeated ALK and PK. The UK National Transplant Registry study showed that repeat PK was associated with worse long-term graft survival than repeat DALK.[<xref rid="R12" ref-type="bibr">12</xref>] More studies have compared the outcomes of secondary PK and EK and reported conflicting results. The Australian Corneal Graft Registry reported that repeat PK had superior graft survival compared with repeat DALK.[<xref rid="R19" ref-type="bibr">19</xref>] In contrast, Ang <italic toggle="yes">et al</italic>.[<xref rid="R20" ref-type="bibr">20</xref>] showed that repeat PK had poorer survival rates than EK in Singapore. A recent report from the UK Transplant Registry found no difference in graft survival between secondary PK and EK.[<xref rid="R12" ref-type="bibr">12</xref>] We also compared the graft survival of the three corneal transplant techniques. Similar to previous studies, short-term survival for DALK and EK was lower than that for PK.[<xref rid="R15" ref-type="bibr">15</xref><xref rid="R21" ref-type="bibr">21</xref>] This may be related to the technical difficulties associated with DALK and EK, resulting in high graft failure rates in a short period. However, long-term survival was better for DALK and EK than for PK, and the regraft survival time was longer for DALK and EK than for PK; however, the differences were not statistically significant. These results demonstrate that DALK and EK can be used as alternatives to PK surgery for failed corneal grafts, potentially providing better long-term outcomes while avoiding the disadvantages of PK.</p><p>Several studies have demonstrated that survival after keratoplasty decreases with repeat keratoplasty procedures.[<xref rid="R10" ref-type="bibr">10</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R23" ref-type="bibr">23</xref>] In this study, we found a decrease in survival time with repeat keratoplasties. However, the cumulative survival proportion was similar for the first and multiple regrafts during the first year after transplantation. Thereafter, it declined faster for multiple regrafts at 35.3% for multiple regrafts and 62.7% for the first regrafts at 5 years. The number of regrafts had a hazard ratio of 1.559 in the univariate analysis, but this did not reach statistical significance (<italic toggle="yes">P</italic> = 0.161).</p><p>We analyzed the risk factors for repeat keratoplasty and found that graft rejection was associated with an increased risk of graft failure. Graft rejection was the most common postoperative complication, occurring in 62 cases (25.51%), with 34 cases ultimately failing despite aggressive anti-rejection therapy. The response rate in our study was more optimistic than the reports by Bersudsky <italic toggle="yes">et al.</italic>,[<xref rid="R9" ref-type="bibr">9</xref>] who found that almost all repeat grafts did not respond to conservative treatment and ultimately failed. Most international studies have shown that graft rejection is a risk factor for graft failure.[<xref rid="R9" ref-type="bibr">9</xref><xref rid="R10" ref-type="bibr">10</xref><xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref>] Ethnicity is thought to be associated with transplant rejection; for example, non-European and black people are more likely to demonstrate graft rejection.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R24" ref-type="bibr">24</xref>] Our findings revealed that graft rejection is the most important risk factor for repeat corneal graft failure in Asian populations. We also found that patients with corneal vascularization were at a higher risk of rejection, which was consistent with the results of other studies.[<xref rid="R26" ref-type="bibr">26</xref><xref rid="R27" ref-type="bibr">27</xref>] The second most common postoperative complication was elevated IOP (18.9%). In most cases, IOP can be controlled with medication, and elevated IOP is not a risk factor for graft failure in the regression analysis.</p><p>This study had some limitations. First, it was retrospective and had limitations such as unequal follow-up times and loss of follow-up. Patients in remote areas or those who recover well from corneal transplantation are more likely to be lost. Therefore, there may have been undetected or unreported rejections or failures in this study. Second, because of the high dropout rate, the median follow-up period was 17 months, which may have led to overestimating the 5-year graft survival rate of repeat grafts. Third, the number of eyes undergoing DALK and EK was lower than those undergoing PK. Therefore, statistical errors may have affected the results of the comparisons between subgroups and should be interpreted with caution.</p></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>This study represents the first comprehensive examination of indications, surgical techniques, outcomes, and risk factors for repeat corneal transplantation in a Chinese population. Infectious keratitis emerged as the primary leading indication, while graft rejection was the most common reason for repeat keratoplasty. PK is the major surgical procedure used for repeated corneal transplants. However, there is potential for DALK and EK to offer better outcomes and be used more widely to treat graft failure. Specific risk factors for repeat keratoplasty failure in a Chinese population were identified. Preventing and treating postoperative corneal graft rejection may be key to improving the survival of repeat corneal transplants.</p><sec sec-type="funding-statement" id="sec2-9"><title>Financial support and sponsorship</title><p>This study was funded by the National Key R and D Program of China (grant no. 2019YFC0840708).</p></sec><sec sec-type="COI-statement" id="sec2-10"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishino</surname><given-names>T</given-names></name>
<name><surname>Kobayashi</surname><given-names>A</given-names></name>
<name><surname>Yokogawa</surname><given-names>H</given-names></name>
<name><surname>Mori</surname><given-names>N</given-names></name>
<name><surname>Sugiyama</surname><given-names>K</given-names></name></person-group><article-title>Changing indications and surgical techniques for keratoplasty during a 16-year period (2003-2018) at a tertiary referral hospital in Japan</article-title><source>Clin Ophthalmol</source><year>2019</year><volume>13</volume><fpage>1499</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">31496641</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>CY</given-names></name>
<name><surname>Lee</surname><given-names>JK</given-names></name>
<name><surname>Gore</surname><given-names>PK</given-names></name>
<name><surname>Lim</surname><given-names>CY</given-names></name>
<name><surname>Chuck</surname><given-names>RS</given-names></name></person-group><article-title>Keratoplasty in the United States: A 10-year review from 2005 through 2014</article-title><source>Ophthalmology</source><year>2015</year><volume>122</volume><fpage>2432</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">26386848</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>HY</given-names></name>
<name><surname>Ormonde</surname><given-names>S</given-names></name>
<name><surname>Brookes</surname><given-names>NH</given-names></name>
<name><surname>Moffatt</surname><given-names>LS</given-names></name>
<name><surname>McGhee</surname><given-names>CN</given-names></name></person-group><article-title>The indications and outcome of paediatric corneal transplantation in New Zealand: 1991&#x02013;2003</article-title><source>Br J Ophthalmol</source><year>2005</year><volume>89</volume><fpage>404</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15774913</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>XT</given-names></name>
<name><surname>Zhai</surname><given-names>HL</given-names></name>
<name><surname>Cheng</surname><given-names>J</given-names></name>
<name><surname>Kong</surname><given-names>QQ</given-names></name>
<name><surname>Cong</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
<etal/></person-group><article-title>Indications for penetrating keratoplasty and anterior lamellar keratoplasty during 2010-2017</article-title><source>Int J Ophthalmol</source><year>2019</year><volume>12</volume><fpage>1878</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">31850172</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>H</given-names></name>
<name><surname>Lin</surname><given-names>M</given-names></name>
<name><surname>Gou</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>A</given-names></name>
<name><surname>Gu</surname><given-names>F</given-names></name>
<name><surname>Liu</surname><given-names>Q</given-names></name>
<etal/></person-group><article-title>Trends in corneal transplantation and characteristics of donors in the chongqing eye bank, China: A retrospective study, 1999&#x02013;2018</article-title><source>Front Med (Lausanne)</source><year>2021</year><volume>8</volume><fpage>750898</fpage><pub-id pub-id-type="pmid">34778313</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dickman</surname><given-names>MM</given-names></name>
<name><surname>Spekreijse</surname><given-names>LS</given-names></name>
<name><surname>Dunker</surname><given-names>SL</given-names></name>
<name><surname>Winkens</surname><given-names>B</given-names></name>
<name><surname>Berendschot</surname><given-names>T</given-names></name>
<name><surname>van den Biggelaar</surname><given-names>F</given-names></name>
<etal/></person-group><article-title>Long-term outcomes of repeated corneal transplantations: A prospective Dutch Registry study</article-title><source>Am J Ophthalmol</source><year>2018</year><volume>193</volume><fpage>156</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">29963996</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>PC</given-names></name>
<name><surname>Ram</surname><given-names>J</given-names></name></person-group><article-title>Outcomes of repeat keratoplasty for failed therapeutic keratoplasty</article-title><source>Am J Ophthalmol</source><year>2016</year><volume>169</volume><fpage>297</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27469057</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srujana</surname><given-names>D</given-names></name>
<name><surname>Kaur</surname><given-names>M</given-names></name>
<name><surname>Urkude</surname><given-names>J</given-names></name>
<name><surname>Rathi</surname><given-names>A</given-names></name>
<name><surname>Sharma</surname><given-names>N</given-names></name>
<name><surname>Titiyal</surname><given-names>JS</given-names></name></person-group><article-title>Long-term functional and anatomic outcomes of repeat graft after optically failed therapeutic keratoplasty</article-title><source>Am J Ophthalmol</source><year>2018</year><volume>189</volume><fpage>166</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">29550189</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bersudsky</surname><given-names>V</given-names></name>
<name><surname>Blum-Hareuveni</surname><given-names>T</given-names></name>
<name><surname>Rehany</surname><given-names>U</given-names></name>
<name><surname>Rumelt</surname><given-names>S</given-names></name></person-group><article-title>The profile of repeated corneal transplantation</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>461</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11237899</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>LM</given-names></name>
<name><surname>Boyle</surname><given-names>AB</given-names></name>
<name><surname>Niederer</surname><given-names>RL</given-names></name>
<name><surname>Brookes</surname><given-names>NH</given-names></name>
<name><surname>McGhee</surname><given-names>CNJ</given-names></name>
<name><surname>Patel</surname><given-names>DV</given-names></name></person-group><article-title>Repeat corneal transplantation in Auckland, New Zealand: Indications, visual outcomes and risk factors for repeat keratoplasty failure</article-title><source>Clin Exp Ophthalmol</source><year>2019</year><volume>47</volume><fpage>987</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">31268240</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>L</given-names></name>
<name><surname>Song</surname><given-names>Z</given-names></name>
<name><surname>Zhao</surname><given-names>J</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Indications for penetrating keratoplasty in north China</article-title><source>Cornea</source><year>2007</year><volume>26</volume><fpage>1070</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17893536</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aboshiha</surname><given-names>J</given-names></name>
<name><surname>Jones</surname><given-names>MNA</given-names></name>
<name><surname>Hopkinson</surname><given-names>CL</given-names></name>
<name><surname>Larkin</surname><given-names>DFP</given-names></name></person-group><article-title>Differential survival of penetrating and lamellar transplants in management of failed corneal grafts</article-title><source>JAMA Ophthalmol</source><year>2018</year><volume>136</volume><fpage>859</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">29931227</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>JC</given-names></name>
<name><surname>Holland</surname><given-names>SP</given-names></name>
<name><surname>Dubord</surname><given-names>PJ</given-names></name>
<name><surname>Moloney</surname><given-names>G</given-names></name>
<name><surname>McCarthy</surname><given-names>M</given-names></name>
<name><surname>Yeung</surname><given-names>SN</given-names></name></person-group><article-title>Evolving indications for and trends in keratoplasty in British Columbia, Canada, from 2002 to 2011: A 10-year review</article-title><source>Cornea</source><year>2014</year><volume>33</volume><fpage>252</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24457452</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Indications for penetrating keratoplasty in East China, 1994&#x02013;2003</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2005</year><volume>243</volume><fpage>1005</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15906072</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noureddine</surname><given-names>S</given-names></name>
<name><surname>Garcin</surname><given-names>T</given-names></name>
<name><surname>Puyraveau</surname><given-names>M</given-names></name>
<name><surname>Thizy</surname><given-names>A</given-names></name>
<name><surname>Ben Moussa</surname><given-names>O</given-names></name>
<name><surname>Peyret</surname><given-names>B</given-names></name>
<etal/></person-group><article-title>Repeat corneal transplantation: Indication, surgical technique, and early graft failures trends in France from 2004 to 2019</article-title><source>Cell Tissue Bank</source><year>2022</year><volume>23</volume><fpage>729</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">35037182</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wan</surname><given-names>X</given-names></name>
<name><surname>Yao</surname><given-names>W</given-names></name>
<name><surname>Zhao</surname><given-names>S</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
<name><surname>Le</surname><given-names>Q</given-names></name></person-group><article-title>Indications and surgical techniques for repeat corneal transplantation in Eastern China: A twelve-year study</article-title><source>J Ophthalmol</source><year>2021</year><volume>2021</volume><fpage>5514004</fpage><pub-id pub-id-type="pmid">34631163</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baydoun</surname><given-names>L</given-names></name>
<name><surname>van Dijk</surname><given-names>K</given-names></name>
<name><surname>Dapena</surname><given-names>I</given-names></name>
<name><surname>Musa</surname><given-names>FU</given-names></name>
<name><surname>Liarakos</surname><given-names>VS</given-names></name>
<name><surname>Ham</surname><given-names>L</given-names></name>
<etal/></person-group><article-title>Repeat Descemet membrane endothelial keratoplasty after complicated primary Descemet membrane endothelial keratoplasty</article-title><source>Ophthalmology</source><year>2015</year><volume>122</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">25200401</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>T</given-names></name>
<name><surname>Qi</surname><given-names>X</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Gao</surname><given-names>H</given-names></name></person-group><article-title>Clinical characteristics and outcomes of short-term repeat corneal transplantation</article-title><source>Ocul Immunol Inflamm</source><year>2022</year><volume>30</volume><fpage>855</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">33555976</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keane</surname><given-names>MC</given-names></name>
<name><surname>Galettis</surname><given-names>RA</given-names></name>
<name><surname>Mills</surname><given-names>RA</given-names></name>
<name><surname>Coster</surname><given-names>DJ</given-names></name>
<name><surname>Williams</surname><given-names>KA</given-names></name>; <collab>Contributors to the Australian Corneal Graft Registry</collab></person-group><article-title>A comparison of endothelial and penetrating keratoplasty outcomes following failed penetrating keratoplasty: A registry study</article-title><source>Br J Ophthalmol</source><year>2016</year><volume>100</volume><fpage>1569</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">26892633</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ang</surname><given-names>M</given-names></name>
<name><surname>Ho</surname><given-names>H</given-names></name>
<name><surname>Wong</surname><given-names>C</given-names></name>
<name><surname>Htoon</surname><given-names>HM</given-names></name>
<name><surname>Mehta</surname><given-names>JS</given-names></name>
<name><surname>Tan</surname><given-names>D</given-names></name></person-group><article-title>Endothelial keratoplasty after failed penetrating keratoplasty: An alternative to repeat penetrating keratoplasty</article-title><source>Am J Ophthalmol</source><year>2014</year><volume>158</volume><fpage>1221</fpage><lpage>7.e1</lpage><pub-id pub-id-type="pmid">25152499</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dickman</surname><given-names>MM</given-names></name>
<name><surname>Peeters</surname><given-names>JM</given-names></name>
<name><surname>van den Biggelaar</surname><given-names>FJ</given-names></name>
<name><surname>Ambergen</surname><given-names>TA</given-names></name>
<name><surname>van Dongen</surname><given-names>MC</given-names></name>
<name><surname>Kruit</surname><given-names>PJ</given-names></name>
<etal/></person-group><article-title>Changing practice patterns and long-term outcomes of endothelial versus penetrating keratoplasty: A Prospective Dutch registry study</article-title><source>Am J Ophthalmol</source><year>2016</year><volume>170</volume><fpage>133</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">27497603</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>TL</given-names></name>
<name><surname>Coster</surname><given-names>DJ</given-names></name>
<name><surname>Williams</surname><given-names>KA</given-names></name></person-group><article-title>Repeat penetrating corneal transplantation in patients with keratoconus</article-title><source>Ophthalmology</source><year>2011</year><volume>118</volume><fpage>1538</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">21459452</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Claesson</surname><given-names>M</given-names></name>
<name><surname>Armitage</surname><given-names>WJ</given-names></name></person-group><article-title>Clinical outcome of repeat penetrating keratoplasty</article-title><source>Cornea</source><year>2013</year><volume>32</volume><fpage>1026</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">23591148</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Son</surname><given-names>HS</given-names></name>
<name><surname>Lum</surname><given-names>F</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name>
<name><surname>Schein</surname><given-names>O</given-names></name>
<name><surname>Pramanik</surname><given-names>S</given-names></name>
<name><surname>Srikumaran</surname><given-names>D</given-names></name></person-group><article-title>Risk factors for repeat keratoplasty after endothelial keratoplasty-An IRIS registry analysis</article-title><source>Am J Ophthalmol</source><year>2022</year><volume>242</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">35738395</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zafar</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>P</given-names></name>
<name><surname>Woreta</surname><given-names>FA</given-names></name>
<name><surname>Aziz</surname><given-names>K</given-names></name>
<name><surname>Makary</surname><given-names>M</given-names></name>
<name><surname>Srikumaran</surname><given-names>D</given-names></name></person-group><article-title>Risk factors for repeat keratoplasty after endothelial keratoplasty in the medicare population</article-title><source>Am J Ophthalmol</source><year>2021</year><volume>221</volume><fpage>287</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">32791066</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bachmann</surname><given-names>BO</given-names></name>
<name><surname>Laaser</surname><given-names>K</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name>
<name><surname>Kruse</surname><given-names>FE</given-names></name></person-group><article-title>A method to confirm correct orientation of descemet membrane during descemet membrane endothelial keratoplasty</article-title><source>Am J Ophthalmol</source><year>2010</year><volume>149</volume><fpage>922</fpage><lpage>925.e2</lpage><pub-id pub-id-type="pmid">20346440</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Immune privilege and angiogenic privilege of the cornea</article-title><source>Chem Immunol Allergy</source><year>2007</year><volume>92</volume><fpage>50</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17264482</pub-id>
</element-citation></ref></ref-list></back></article>